LILRB3 and B-cell non-Hodgkin lymphoma: To test the potential of LILRB3 ligation to suppress the allogeneic immune response, adult humanized mice were treated with the agonistic LILRB3 mAb (A1) and the engraftment of allogeneic human B cell lymphoma cells, derived from an unrelated donor (36, 37), was monitored over time (Figure 4A).